Show simple item record

dc.contributor.authorHov, Karen Roksund
dc.contributor.authorNeerland, Bjørn Erik
dc.contributor.authorUndseth, Øystein
dc.contributor.authorWyller, Vegard Bruun Bratholm
dc.contributor.authorMacLullich, Alasdair M.J.
dc.contributor.authorQvigstad, Eirik
dc.contributor.authorSkovlund, Eva
dc.contributor.authorWyller, Torgeir Bruun
dc.date.accessioned2019-09-19T11:10:30Z
dc.date.available2019-09-19T11:10:30Z
dc.date.created2019-06-27T15:11:02Z
dc.date.issued2019
dc.identifier.citationInternational Journal of Geriatric Psychiatry. 2019, 34 (7), 974-981.nb_NO
dc.identifier.issn0885-6230
dc.identifier.urihttp://hdl.handle.net/11250/2617650
dc.description.abstractObjectives The aim of this double‐blinded randomised placebo‐controlled trial was to investigate the efficacy of clonidine for delirium in medical inpatients greater than 65 years. Methods Acutely admitted medical patients greater than 65 years with delirium or subsyndromal delirium were eligible for inclusion. Included patients were given a loading dose of either placebo or clonidine; 75 μg every third hour up to a maximum of four doses to reach steady state and further 75 μg twice daily until delirium free for 2 days, discharge or a maximum of 7 days of treatment. The primary endpoint was the trajectory of the Memorial Delirium Assessment Scale (MDAS) for the 7 days of treatment. Presence of delirium according to the Diagnostic and Statistical Manual of Mental Disorders (DSM‐5) criteria and severity measured by MDAS were assessed daily until discharge or a maximum of 7 days after end of treatment. Results Because of slower enrolment than anticipated, the study was halted early. Ten patients in each group were studied. The low recruitment rate was mainly due to the presence of multiple patient exclusion criteria for patient safety. There was no significant difference between the treatment group in the primary endpoint comparing the trajectory of MDAS for the 7 days of treatment using mixed linear models with log transformation, (P = .60). The treatment group did not have increased adverse effects. Conclusions No effect of clonidine for delirium was found, although the study was under powered. Further studies in less frail populations are now required.nb_NO
dc.language.isoengnb_NO
dc.publisherWileynb_NO
dc.titleThe Oslo Study of Clonidine in Elderly Patients with Delirium; LUCID: a randomised placebo-controlled trialnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionacceptedVersionnb_NO
dc.source.pagenumber974-981nb_NO
dc.source.volume34nb_NO
dc.source.journalInternational Journal of Geriatric Psychiatrynb_NO
dc.source.issue7nb_NO
dc.identifier.doi10.1002/gps.5098
dc.identifier.cristin1708394
dc.description.localcodeLocked until 22.3.2020 due to copyright restrictions. This is the peer reviewed version of an article, which has been published in final form at [https://doi.org/10.1002/gps.5098]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.nb_NO
cristin.unitcode194,65,20,0
cristin.unitnameInstitutt for samfunnsmedisin og sykepleie
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record